Show Me Your Care Plan™: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma
41st Annual Miami Breast Cancer Conference®
Community Practice Connections™: What’s Next for Patients with Breast Cancer, and How Can We Effectively Optimize PARP-, HER2/3-, and TROP2-Targeted Regimens in Treatment Plans?
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
7th Annual International Congress on Oncology & Pathology™: Towards Harmonization of Pathology and Oncology Standards
3rd Annual International Congress on the Future of Women’s Health™
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
The 14th Asia-Pacific Primary Liver Cancer Expert Meeting
FDA Approves Radiohybrid PET Diagnostic Agent Posluma for PSMA-Positive Lesions in Prostate CancerMay 30th 2023
The PET diagnostic imaging agent, flotufolastat F 18 injection has been approved by the FDA for the identification of prostate-specific membrane antigen–positive lesions in men with prostate cancer
Improvements in Health Systems Model Reduces Disparities in Leukemia Survival in Low-Income CountriesMay 25th 2023
Pediatric patients with leukemia in low- and middle-income countries saw improvements in survival outcomes following implementation of the WHO Framework for Action model.
Final OS Analysis Confirms Benefit of Pembrolizumab/Chemotherapy With or Without Bevacizumab in Frontline Cervical CancerMay 25th 2023
Updated findings from KEYNOTE-826 support the use of pembrolizumab plus chemotherapy with or without bevacizumab for select patients with cervical cancer.
Minimally Invasive Distal Pancreatectomy Proves Noninferior to Open Distal Pancreatectomy in Resectable Pancreatic CancerMay 25th 2023
Minimally invasive distal pancreatectomy was a safe and effective alternative compared with open distal pancreatectomy in patients with resectable pancreatic cancer.
Pembrolizumab Plus Lenvatinib Gains NICE Recommendation for Previously Treated Advanced or Recurrent Endometrial CancerMay 24th 2023
The United Kingdom’s National Institute for Health and Care Excellence has updated their guidelines to recommend pembrolizumab plus lenvatinib for patients with previously treated endometrial cancer.
Elizabeth Cullen Discusses Avasopasem Manganese As A Potential Mucositis Management Strategy in Head and Neck CancersMay 22nd 2023
Elizabeth R. Cullen, MSN, ARNP, provides an overview of avasopasem manganese and its potential role in reducing severe oral mucositis for patients undergoing radiotherapy.